<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01704508</url>
  </required_header>
  <id_info>
    <org_study_id>Eurartesim-2012</org_study_id>
    <nct_id>NCT01704508</nct_id>
  </id_info>
  <brief_title>Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A</brief_title>
  <official_title>Efficacy and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bandim Health Project</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bandim Health Project</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Plasmodium falciparum causes malaria and approximately 665 000 deaths each year. chloroquine&#xD;
      and sulphadoxine-pyrimethamine resistant P. falciparum are widespread. An artemisinin&#xD;
      derivative combined with lumefantrine, amodiaquine or piperaquine is therefore recommended&#xD;
      for the treatment of malaria in Africa. However, artemisinin resistance appears to be&#xD;
      developing and resistance/tolerance to amodiaquine and lumefantrine exists. We are presently&#xD;
      conducting a study in Guinea-Bissau. Preliminary data indicates that the effectiveness and&#xD;
      availability of artemether-lumefantrine (AL), the 1st line drug, is poor. Consequently there&#xD;
      is a need for another treatment option. Dihydroartemisinin-piperaquine (DP) has been shown to&#xD;
      be efficacious and well tolerated in several African countries and is therefore such an&#xD;
      option. A clinical trial comparing the safety and efficacy of artemether-lumefantrine and&#xD;
      dihydroartemisinin-piperaquine is therefore needed.&#xD;
&#xD;
      Parents to children seeking Bandim Health Centre (CSB) with symptoms compatible with malaria&#xD;
      will be informed of the study. If accepting and the child fulfil the inclusion criteria, the&#xD;
      child will be randomised to treatment with either AL or DP. The treatment will be given&#xD;
      supervised at the health centre in the morning and the evening on day 0, day 1, and day 2.&#xD;
&#xD;
      At each visit and in the morning on day 3, the child will be examined, the mother asked for&#xD;
      any symptoms and signs of side-effects, the temperature measured. Furthermore, a blood sample&#xD;
      will be taken for examination of malaria parasites. On day 0 samples for measurement of&#xD;
      antimalarial drugs and for genotyping of the parasites will be taken on filterpaper. In a&#xD;
      subgroup of 50 children a blood sample for in vitro culturing and for analysis of the number&#xD;
      of leucocytes will also be taken.&#xD;
&#xD;
      After having finished the treatment the children will be followed on day 7 and then once a&#xD;
      week until day 42. At each visit the condition of the child will be examined and a&#xD;
      bloodsample taken for examination of parasites in the blood. Furthermore, a filterpaper&#xD;
      bloodsample will be collected for measurement of the drug concentration of if the child has&#xD;
      recrudescence for genotyping of the parasites. On day 0, 3 and 42 the haemoglobin level will&#xD;
      be examined.&#xD;
&#xD;
      The result of the two treatments will be evaluated by comparing the number of children with&#xD;
      recurrent parasitaemia, both corrected and uncorrected (recrudescence vs. reinfections). This&#xD;
      will be presented as adequate clinical and parasitological response rates PCR-corrected and&#xD;
      PCR-uncorrected. Furthermore, the chance in haemoglobin level from day 0 till day 3 and till&#xD;
      day 42 will be compared. The concentration of the antimalarial drug in the blood samples&#xD;
      taken at the visit before the re-parasitaemia will be capered to the concentrations in&#xD;
      children without re-parasitaemia.&#xD;
&#xD;
      Assuming a 20% loss to follow up a total of 346 children should be included. For the children&#xD;
      included, health care and medications at Bandim Health Centre will be free during the study&#xD;
      period but no other gifts or payments will be made.&#xD;
&#xD;
      Results will be presented to the staff at the Bandim health centre and the ministry of Health&#xD;
      and will be published in an international peer reviewed journal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Plasmodium falciparum causes malaria and approximately 665 000 deaths each year.&#xD;
      Previously chloroquine (CQ) and sulphadoxine-pyrimethamine were the principle drugs for the&#xD;
      treatment of malaria. Due to widespread resistance to these drugs1, the World Health&#xD;
      Organization recommends that P. falciparum in Africa should be treated with artemisinin +&#xD;
      amodiaquine, artemether + lumefantrine (AL) or dihydroartemisinin + piperaquine2 (DP).&#xD;
      However, resistance to artemisinins appears to be developing3,4, resistance to amodiaquine&#xD;
      exists2 and treatment with AL rapidly selects for parasites with increased tolerance (5 times&#xD;
      higher inhibitory concentration) to lumefantrine5-7.&#xD;
&#xD;
      In Guinea-Bissau, CQ remained efficacious until replaced by AL. This is explained by the use&#xD;
      of a unique well tolerated high dose treatment schedule 8-10. Since the introduction of AL in&#xD;
      2008, the number of children with malaria has increased manyfold in Bissau in contrast with&#xD;
      other African countries. Our data suggests that this increase is due unavailability of AL,&#xD;
      poorer than expected effectiveness of AL and to an increased use of the second-line drug&#xD;
      quinine. Quinine is typically given for 3 instead of 7 days and has very poor efficacy when&#xD;
      used thus11. To counter this Guinea-Bissau needs an alternative cheap and easily dosed 2nd&#xD;
      line drug that can also be used when AL is not available or when funding for AL no longer&#xD;
      exists.&#xD;
&#xD;
      Dihydroartemisinin+piperaquine is a safe and well tolerated artemisinin based combination12.&#xD;
      DP is taken once daily and has been shown to be highly efficacious (&gt;95%) in several African&#xD;
      settings13,14. DP also protects from re-infection for longer than AL14. As such this is a&#xD;
      drug that could become an attractive treatment option in Guinea-Bissau. It has however, never&#xD;
      been used in the country.&#xD;
&#xD;
      Aim Conduct an efficacy study with artemether + lumefantrine and dihydroartemisinin +&#xD;
      piperaquine&#xD;
&#xD;
        1. To measure the efficacy and safety of AL and DP in children aged 6 months to 12 years&#xD;
           suffering from uncomplicated P. falciparum malaria.&#xD;
&#xD;
        2. To determine the capacity of each drug combination to protect against re-infection.&#xD;
&#xD;
        3. To differentiate recrudescence from re-infections using PCR based methods&#xD;
&#xD;
        4. To determine whole blood concentrations of lumefantrine and piperaquine the week before&#xD;
           reparasitaemia&#xD;
&#xD;
        5. To determine haemoglobin values on days 0, 3 and 42&#xD;
&#xD;
        6. To determine differential white blood cell counts on days 0, 3, 7, 14 and 21&#xD;
&#xD;
        7. To determine genetic polymorphisms in P. falciparum causing reparasitaemia,&#xD;
&#xD;
        8. To culture parasites from 50 children for further characterisation of P. falciparum&#xD;
           geno- and phenotypes.&#xD;
&#xD;
           2. Methods Study design This will be an open label, randomized, non inferiority trial&#xD;
           conducted at the Bandim health centre, Guinea-Bissau. Children with uncomplicated&#xD;
           malaria who meet study inclusion criteria will be enrolled, randomised to treatment with&#xD;
           either AL or DP, treated on site and monitored for 42 days. The follow up will consist&#xD;
           of a fixed schedule of check-up visits and corresponding clinical and laboratory&#xD;
           examinations. The proportion of children experiencing therapeutic failure during the&#xD;
           follow-up period will be used to estimate the efficacy of the study drugs. PCR analysis&#xD;
           will be used to distinguish between a true recrudescence due to treatment failure and&#xD;
           episodes of re-infection.&#xD;
&#xD;
           Study Site and population Children aged 6 months to 12 years with uncomplicated P.&#xD;
           falciparum malaria that attend the Bandim health centre.&#xD;
&#xD;
           Timing and duration of the study The study will start in November 2012 and continue&#xD;
           until 350 children are included. If this is not achieved in one year the study will run&#xD;
           for 2 years.&#xD;
&#xD;
           Inclusion criteria A) Age ≥6 months, and &lt;13 years. B) Mono-infection with P. falciparum&#xD;
           detected by microscopy. C) Parasitemia of 1.000-200.000/µl asexual forms. D) Axillary&#xD;
           temperature ≥37.5 ˚C or a history of fever within 24 hours. E) Ability to swallow oral&#xD;
           medication.&#xD;
&#xD;
           F) Ability and willingness to comply with the study protocol for the duration of the&#xD;
           study and to comply with the study visit schedule. G) Informed consent from a parent or&#xD;
           guardian&#xD;
&#xD;
           Exclusion criteria A) Signs or symptoms of severe malaria including the following&#xD;
           symptoms Prostration. Impaired consciousness. Respiratory distress. Repeated generalised&#xD;
           convulsions (three or more per 24 hours or 2 witnessed seizures in 24 hours).&#xD;
           Circulatory collapse. Abnormal bleeding. Jaundice. Haemoglobinuria (dark red/black&#xD;
           urine). Severe anaemia (Haemoglobin &lt;5g/dl). Hyperparasitaemia (&gt;200.000/ µl asexual&#xD;
           forms) B) Presence of general danger signs in children under 5 including the following&#xD;
           Prostration. Respiratory distress. Haemoglobin &lt;5g/dl. Two or more convulsions within 24&#xD;
           hours. Persistent vomiting C) Presence of severe malnutrition. D) Any evidence of&#xD;
           chronic disease or acute infection other than malaria. E) Regular medication which may&#xD;
           interfere with antimalarial pharmacokinetics. F) History of hypersensitivity reactions&#xD;
           or contraindications to AL, DP or quinine.&#xD;
&#xD;
           G) Domicile outside the study area.&#xD;
&#xD;
           Loss to follow up If a child is not seen on the day of follow up the child will be&#xD;
           sought at home on two consecutive days and if possible contacted by mobile phone. At&#xD;
           each subsequent weekly follow up three new attempts to see the child will be made.&#xD;
&#xD;
           3. Treatment Antimalarial treatment Treatment with AL will be given according to a&#xD;
           6-dose regime. Treatment with DP will be given according to a 3 dose regime. Tablets of&#xD;
           AL (20 mg artemether and 120 mg lumefantrine) will be obtained from the manufacturer.&#xD;
           Tablets of DP (Eurartesim®) with 160mg/20mg or 320mg/40mg obtained from Sigma-Tau.&#xD;
&#xD;
           Block Randomization Identical slips of paper specifying treatment arm AL or DP will be&#xD;
           put into an envelope. Each envelope will contain 20 slips from each group and children&#xD;
           will randomly select one slip.&#xD;
&#xD;
           Concomitant treatment and medication that should not be used Paracetamol will be used to&#xD;
           treat fever. Iron and vitamin supplementation will be given if required. Prior treatment&#xD;
           with an antimalarial drug will not be considered as exclusion criteria. Children taking&#xD;
           any drug with antimalarial activity (including antibiotics such as tetracycline or&#xD;
           azithromycin) during the study period will be withdrawn.&#xD;
&#xD;
           Rescue treatment If children vomit twice, they will receive therapy with quinine&#xD;
           intramuscularly and will be withdrawn from the study. Any child with signs of severe or&#xD;
           complicated malaria will be treated according to recommendations of the attending nurse.&#xD;
           If a child meets criteria for early treatment failure, he or she will receive parenteral&#xD;
           quinine. If a child meets criteria for late treatment failure he or she will be&#xD;
           re-treated with AL.&#xD;
&#xD;
           4. Evaluation Criteria Efficacy and safety evaluation Treatment outcomes will be early&#xD;
           treatment failure, late clinical failure, late parasitological failure or adequate&#xD;
           clinical and parasitological response as defined by the WHO2.&#xD;
&#xD;
           Safety end points The incidence of any adverse event including neutropenia will be&#xD;
           documented. All children will be asked routinely about previous symptoms and about&#xD;
           symptoms that have emerged since the previous follow up visit. When clinically&#xD;
           indicated, children will be evaluated and treated appropriately. All adverse events will&#xD;
           be recorded in the case record forms.&#xD;
&#xD;
           Clinical evaluation All children will be evaluated by an attending study nurse and the&#xD;
           examination will include a physical examination, body weight, body (axillary)&#xD;
           temperature as shown in table 3&#xD;
&#xD;
           Microscopic examination Two thick and thin blood films for parasite counts and species&#xD;
           identification will be obtained as shown in table 3 and whenever a child returns to the&#xD;
           Bandim health centre. Slides will be stained using freshly prepared Giemsa and examined&#xD;
           with 1000 x magnification. The number of asexual parasites per 200 white blood cells&#xD;
           will be counted or, if parasitaemia is high, the number of white blood cells per 500&#xD;
           parasites will be counted. Parasite density will be assessed independently by 2&#xD;
           qualified microscopists. Discordant results will be read a third time.&#xD;
&#xD;
           Genotyping, antimalarial drug concentration, haemoglobin and white blood cell count&#xD;
           100µL of blood will be collected on Whatman 3MM filter-paper using a capillary tube on&#xD;
           day 0, 7, 14, 21, 28, 35, 42 and whenever reparasitaemia is detected. Filter-papers will&#xD;
           be dried and then placed inside separate sealed plastic bags. Filter-papers and bags&#xD;
           will be labelled with study number date and follow up day. The samples will be stored at&#xD;
           -20˚C. Blood samples will be obtained at the same time that blood is taken for&#xD;
           microscopy.&#xD;
&#xD;
           In order to differentiate recrudescence from a re-infection genotyping using sequential&#xD;
           analysis of pfglurp, pfmsp1 and pfmsp2 will be done21.&#xD;
&#xD;
           The proportion of resistance associated genotypes in resistance associated genes&#xD;
           including pfcrt, pfmdr1, pfmrp1 and pfcmu will be determined. Genotyping will be done at&#xD;
           Karolinska Institutet, Stockholm, Sweden and/or Universidade do Minho, Portugal.&#xD;
&#xD;
           Drug concentrations will be assessed on the week prior to reparasitaemia at Mahidol&#xD;
           University Bangkok using high performance liquid chromatography (HPLC).&#xD;
&#xD;
           Haemoglobin concentration will be determined on day 0, 3 and 42 using a haemocueTM At&#xD;
           the same time that blood sampling for microscopy is done on Day 0, exactly 200μL of&#xD;
           blood will also be taken for in vitro culturing from 50 patients. The blood will be put&#xD;
           into medium and grown in vitro in an incubator at 37 ˚C. When a culture is established&#xD;
           it will be frozen in liquid nitrogen for transport to Sweden or Portugal where extensive&#xD;
           drug assays will be carried out.&#xD;
&#xD;
           5. Study Assessment Screening and enrolment As part of the routine medical services&#xD;
           provided at the health centre, all children with symptoms suggestive of malaria will be&#xD;
           screened for malaria using a rapid diagnostic test. Positive tests are confirmed by&#xD;
           microscopy. Children fulfilling inclusion critera will be invited to participate in the&#xD;
           study following informed consent.&#xD;
&#xD;
           Follow up Children will be given a unique personal identification number and be given&#xD;
           treatment after informed consent. The basic follow up schedule is shown below.&#xD;
           Treatments, information to the children, clinical observations and adverse events will&#xD;
           be recorded in the clinical record forms. The children will come to the health centre on&#xD;
           days 0, 1, 2, 3, 7, 14, 21, 28, 35 and 42. If a child is not seen at the health centre&#xD;
           he/she will be visited at home.&#xD;
&#xD;
           6. Data Management The principle investigator will ensure that the study protocol is&#xD;
           strictly adhered to and that data are correctly collected and recorded on the case&#xD;
           record form. Data will be entered into an EpiData database during the study.&#xD;
&#xD;
           7. Sample size The PCR corrected day 42 ACPR of AL was 97% in 2008 ( = before the&#xD;
           national recommendation was changed in favour of A). It is likely that DP should be as&#xD;
           efficacious as AL and it is therefore appropriate to conduct a non-inferiority trial13.&#xD;
           Assuming 97% ACPR for both treatments, 5% significance level (alpha), 80% power (1-beta)&#xD;
           and a non-inferiority limit (d) of 5% 144 children are required in each arm. Assuming a&#xD;
           20% loss to follow up a total of 346 children should be included.&#xD;
&#xD;
           Analysis of data The data will be analysed using survival estimates of per protocol&#xD;
           treatment failure rates but also intention to treat treatment failure rates. Final&#xD;
           analysis will include a description of included children, proportions of adverse events&#xD;
           and any serious adverse events, the proportion of children withdrawn or lost to follow&#xD;
           up, the cumulative PCR corrected and uncorrected success and failure rates on day 42 and&#xD;
           the proportion of early, late clinical and late parasitological treatment failures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adequate clinical and parasitological response rate</measure>
    <time_frame>42 days</time_frame>
    <description>The data will be analysed using survival estimates of per protocol treatment failure rates but also intention to treat treatment failure rates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the safety of AL and DP</measure>
    <time_frame>42 days</time_frame>
    <description>Self-reported signs and symptoms, clinical evaluations during treatment, day 7 and then weekly until day 42. leucocytes day 0, 3, 7, 14 and 21.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To determine the capacity of each drug combination to protect against re-infection and to differentiate recrudescence from re-infections using PCR based methods</measure>
    <time_frame>42 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Genetic polymorphisms in P. falciparum causing reparasitaemia (by PCR) and in 50 children perform a characterisation of P. falciparum geno- and phenotypes.</measure>
    <time_frame>42 days</time_frame>
    <description>For all children with re-parasitaemia genetic polymorfisms will be established by PCR, and in additional 50 children further characterisation using cultures will be done</description>
  </other_outcome>
  <other_outcome>
    <measure>haemoglobin values</measure>
    <time_frame>days 0, 3 and 42</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">346</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Artemether-lumefantrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6-dose regime will be used:</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dihydroartemisinin-piperaquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 3 dose regime will be used</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine</intervention_name>
    <arm_group_label>Artemether-lumefantrine</arm_group_label>
    <other_name>Coartem (R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroartemisinin-piperaquine</intervention_name>
    <arm_group_label>Dihydroartemisinin-piperaquine</arm_group_label>
    <other_name>Eurartesim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A) Age ≥6 months, and &lt;13 years. B) Mono-infection with P. falciparum detected by&#xD;
        microscopy. C) Parasitemia of 1.000-200.000/µl asexual forms. D) Axillary temperature ≥37.5&#xD;
        ˚C or a history of fever within 24 hours. E) Ability to swallow oral medication.&#xD;
&#xD;
        F) Ability and willingness to comply with the study protocol for the duration of the study&#xD;
        and to comply with the study visit schedule. G) Informed consent from a parent or guardian&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A) Signs or symptoms of severe malaria, incl. hyperparasitaemia (&gt;200.000/ µl asexual&#xD;
        forms) B) Presence of general danger signs in children under 5 C) Presence of severe&#xD;
        malnutrition. D) Any evidence of chronic disease or acute infection other than malaria. E)&#xD;
        Regular medication which may interfere with antimalarial pharmacokinetics. F) History of&#xD;
        hypersensitivity reactions or contraindications to AL, DP or quinine.&#xD;
&#xD;
        G) Domicile outside the study area.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bandim Health Project</name>
      <address>
        <city>Bissau</city>
        <country>Guinea-Bissau</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Guinea-Bissau</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>October 9, 2012</study_first_submitted>
  <study_first_submitted_qc>October 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2012</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Falciparum malaria</keyword>
  <keyword>children</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Artemether, Lumefantrine Drug Combination</mesh_term>
    <mesh_term>Artenimol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01704508
org study id: Eurartesim-2012
nct id: NCT01704508
lead sponsor: 
collaborator: 
has dmc: No
Plasmodium falciparum causes malaria and approximately 665 000 deaths each year. chloroquine
      and sulphadoxine-pyrimethamine resistant P. falciparum are widespread. An artemisinin
      derivative combined with lumefantrine, amodiaquine or piperaquine is therefore recommended
      for the treatment of malaria in Africa. However, artemisinin resistance appears to be
      developing and resistance/tolerance to amodiaquine and lumefantrine exists. We are presently
      conducting a study in Guinea-Bissau. Preliminary data indicates that the effectiveness and
      availability of artemether-lumefantrine (AL), the 1st line drug, is poor. Consequently there
      is a need for another treatment option. Dihydroartemisinin-piperaquine (DP) has been shown to
      be efficacious and well tolerated in several African countries and is therefore such an
      option. A clinical trial comparing the safety and efficacy of artemether-lumefantrine and
      dihydroartemisinin-piperaquine is therefore needed.

      Parents to children seeking Bandim Health Centre (CSB) with symptoms compatible with malaria
      will be informed of the study. If accepting and the child fulfil the inclusion criteria, the
      child will be randomised to treatment with either AL or DP. The treatment will be given
      supervised at the health centre in the morning and the evening on day 0, day 1, and day 2.

      At each visit and in the morning on day 3, the child will be examined, the mother asked for
      any symptoms and signs of side-effects, the temperature measured. Furthermore, a blood sample
      will be taken for examination of malaria parasites. On day 0 samples for measurement of
      antimalarial drugs and for genotyping of the parasites will be taken on filterpaper. In a
      subgroup of 50 children a blood sample for in vitro culturing and for analysis of the number
      of leucocytes will also be taken.

      After having finished the treatment the children will be followed on day 7 and then once a
      week until day 42. At each visit the condition of the child will be examined and a
      bloodsample taken for examination of parasites in the blood. Furthermore, a filterpaper
      bloodsample will be collected for measurement of the drug concentration of if the child has
      recrudescence for genotyping of the parasites. On day 0, 3 and 42 the haemoglobin level will
      be examined.

      The result of the two treatments will be evaluated by comparing the number of children with
      recurrent parasitaemia, both corrected and uncorrected (recrudescence vs. reinfections). This
      will be presented as adequate clinical and parasitological response rates PCR-corrected and
      PCR-uncorrected. Furthermore, the chance in haemoglobin level from day 0 till day 3 and till
      day 42 will be compared. The concentration of the antimalarial drug in the blood samples
      taken at the visit before the re-parasitaemia will be capered to the concentrations in
      children without re-parasitaemia.

      Assuming a 20% loss to follow up a total of 346 children should be included. For the children
      included, health care and medications at Bandim Health Centre will be free during the study
      period but no other gifts or payments will be made.

      Results will be presented to the staff at the Bandim health centre and the ministry of Health
      and will be published in an international peer reviewed journal.
Background Plasmodium falciparum causes malaria and approximately 665 000 deaths each year.
      Previously chloroquine (CQ) and sulphadoxine-pyrimethamine were the principle drugs for the
      treatment of malaria. Due to widespread resistance to these drugs1, the World Health
      Organization recommends that P. falciparum in Africa should be treated with artemisinin +
      amodiaquine, artemether + lumefantrine (AL) or dihydroartemisinin + piperaquine2 (DP).
      However, resistance to artemisinins appears to be developing3,4, resistance to amodiaquine
      exists2 and treatment with AL rapidly selects for parasites with increased tolerance (5 times
      higher inhibitory concentration) to lumefantrine5-7.

      In Guinea-Bissau, CQ remained efficacious until replaced by AL. This is explained by the use
      of a unique well tolerated high dose treatment schedule 8-10. Since the introduction of AL in
      2008, the number of children with malaria has increased manyfold in Bissau in contrast with
      other African countries. Our data suggests that this increase is due unavailability of AL,
      poorer than expected effectiveness of AL and to an increased use of the second-line drug
      quinine. Quinine is typically given for 3 instead of 7 days and has very poor efficacy when
      used thus11. To counter this Guinea-Bissau needs an alternative cheap and easily dosed 2nd
      line drug that can also be used when AL is not available or when funding for AL no longer
      exists.

      Dihydroartemisinin+piperaquine is a safe and well tolerated artemisinin based combination12.
      DP is taken once daily and has been shown to be highly efficacious (>95%) in several African
      settings13,14. DP also protects from re-infection for longer than AL14. As such this is a
      drug that could become an attractive treatment option in Guinea-Bissau. It has however, never
      been used in the country.

      Aim Conduct an efficacy study with artemether + lumefantrine and dihydroartemisinin +
      piperaquine

        1. To measure the efficacy and safety of AL and DP in children aged 6 months to 12 years
           suffering from uncomplicated P. falciparum malaria.

        2. To determine the capacity of each drug combination to protect against re-infection.

        3. To differentiate recrudescence from re-infections using PCR based methods

        4. To determine whole blood concentrations of lumefantrine and piperaquine the week before
           reparasitaemia

        5. To determine haemoglobin values on days 0, 3 and 42

        6. To determine differential white blood cell counts on days 0, 3, 7, 14 and 21

        7. To determine genetic polymorphisms in P. falciparum causing reparasitaemia,

        8. To culture parasites from 50 children for further characterisation of P. falciparum
           geno- and phenotypes.

           2. Methods Study design This will be an open label, randomized, non inferiority trial
           conducted at the Bandim health centre, Guinea-Bissau. Children with uncomplicated
           malaria who meet study inclusion criteria will be enrolled, randomised to treatment with
           either AL or DP, treated on site and monitored for 42 days. The follow up will consist
           of a fixed schedule of check-up visits and corresponding clinical and laboratory
           examinations. The proportion of children experiencing therapeutic failure during the
           follow-up period will be used to estimate the efficacy of the study drugs. PCR analysis
           will be used to distinguish between a true recrudescence due to treatment failure and
           episodes of re-infection.

           Study Site and population Children aged 6 months to 12 years with uncomplicated P.
           falciparum malaria that attend the Bandim health centre.

           Timing and duration of the study The study will start in November 2012 and continue
           until 350 children are included. If this is not achieved in one year the study will run
           for 2 years.

           Inclusion criteria A) Age ≥6 months, and <13 years. B) Mono-infection with P. falciparum
           detected by microscopy. C) Parasitemia of 1.000-200.000/µl asexual forms. D) Axillary
           temperature ≥37.5 ˚C or a history of fever within 24 hours. E) Ability to swallow oral
           medication.

           F) Ability and willingness to comply with the study protocol for the duration of the
           study and to comply with the study visit schedule. G) Informed consent from a parent or
           guardian

           Exclusion criteria A) Signs or symptoms of severe malaria including the following
           symptoms Prostration. Impaired consciousness. Respiratory distress. Repeated generalised
           convulsions (three or more per 24 hours or 2 witnessed seizures in 24 hours).
           Circulatory collapse. Abnormal bleeding. Jaundice. Haemoglobinuria (dark red/black
           urine). Severe anaemia (Haemoglobin <5g/dl). Hyperparasitaemia (>200.000/ µl asexual
           forms) B) Presence of general danger signs in children under 5 including the following
           Prostration. Respiratory distress. Haemoglobin <5g/dl. Two or more convulsions within 24
           hours. Persistent vomiting C) Presence of severe malnutrition. D) Any evidence of
           chronic disease or acute infection other than malaria. E) Regular medication which may
           interfere with antimalarial pharmacokinetics. F) History of hypersensitivity reactions
           or contraindications to AL, DP or quinine.

           G) Domicile outside the study area.

           Loss to follow up If a child is not seen on the day of follow up the child will be
           sought at home on two consecutive days and if possible contacted by mobile phone. At
           each subsequent weekly follow up three new attempts to see the child will be made.

           3. Treatment Antimalarial treatment Treatment with AL will be given according to a
           6-dose regime. Treatment with DP will be given according to a 3 dose regime. Tablets of
           AL (20 mg artemether and 120 mg lumefantrine) will be obtained from the manufacturer.
           Tablets of DP (Eurartesim®) with 160mg/20mg or 320mg/40mg obtained from Sigma-Tau.

           Block Randomization Identical slips of paper specifying treatment arm AL or DP will be
           put into an envelope. Each envelope will contain 20 slips from each group and children
           will randomly select one slip.

           Concomitant treatment and medication that should not be used Paracetamol will be used to
           treat fever. Iron and vitamin supplementation will be given if required. Prior treatment
           with an antimalarial drug will not be considered as exclusion criteria. Children taking
           any drug with antimalarial activity (including antibiotics such as tetracycline or
           azithromycin) during the study period will be withdrawn.

           Rescue treatment If children vomit twice, they will receive therapy with quinine
           intramuscularly and will be withdrawn from the study. Any child with signs of severe or
           complicated malaria will be treated according to recommendations of the attending nurse.
           If a child meets criteria for early treatment failure, he or she will receive parenteral
           quinine. If a child meets criteria for late treatment failure he or she will be
           re-treated with AL.

           4. Evaluation Criteria Efficacy and safety evaluation Treatment outcomes will be early
           treatment failure, late clinical failure, late parasitological failure or adequate
           clinical and parasitological response as defined by the WHO2.

           Safety end points The incidence of any adverse event including neutropenia will be
           documented. All children will be asked routinely about previous symptoms and about
           symptoms that have emerged since the previous follow up visit. When clinically
           indicated, children will be evaluated and treated appropriately. All adverse events will
           be recorded in the case record forms.

           Clinical evaluation All children will be evaluated by an attending study nurse and the
           examination will include a physical examination, body weight, body (axillary)
           temperature as shown in table 3

           Microscopic examination Two thick and thin blood films for parasite counts and species
           identification will be obtained as shown in table 3 and whenever a child returns to the
           Bandim health centre. Slides will be stained using freshly prepared Giemsa and examined
           with 1000 x magnification. The number of asexual parasites per 200 white blood cells
           will be counted or, if parasitaemia is high, the number of white blood cells per 500
           parasites will be counted. Parasite density will be assessed independently by 2
           qualified microscopists. Discordant results will be read a third time.

           Genotyping, antimalarial drug concentration, haemoglobin and white blood cell count
           100µL of blood will be collected on Whatman 3MM filter-paper using a capillary tube on
           day 0, 7, 14, 21, 28, 35, 42 and whenever reparasitaemia is detected. Filter-papers will
           be dried and then placed inside separate sealed plastic bags. Filter-papers and bags
           will be labelled with study number date and follow up day. The samples will be stored at
           -20˚C. Blood samples will be obtained at the same time that blood is taken for
           microscopy.

           In order to differentiate recrudescence from a re-infection genotyping using sequential
           analysis of pfglurp, pfmsp1 and pfmsp2 will be done21.

           The proportion of resistance associated genotypes in resistance associated genes
           including pfcrt, pfmdr1, pfmrp1 and pfcmu will be determined. Genotyping will be done at
           Karolinska Institutet, Stockholm, Sweden and/or Universidade do Minho, Portugal.

           Drug concentrations will be assessed on the week prior to reparasitaemia at Mahidol
           University Bangkok using high performance liquid chromatography (HPLC).

           Haemoglobin concentration will be determined on day 0, 3 and 42 using a haemocueTM At
           the same time that blood sampling for microscopy is done on Day 0, exactly 200μL of
           blood will also be taken for in vitro culturing from 50 patients. The blood will be put
           into medium and grown in vitro in an incubator at 37 ˚C. When a culture is established
           it will be frozen in liquid nitrogen for transport to Sweden or Portugal where extensive
           drug assays will be carried out.

           5. Study Assessment Screening and enrolment As part of the routine medical services
           provided at the health centre, all children with symptoms suggestive of malaria will be
           screened for malaria using a rapid diagnostic test. Positive tests are confirmed by
           microscopy. Children fulfilling inclusion critera will be invited to participate in the
           study following informed consent.

           Follow up Children will be given a unique personal identification number and be given
           treatment after informed consent. The basic follow up schedule is shown below.
           Treatments, information to the children, clinical observations and adverse events will
           be recorded in the clinical record forms. The children will come to the health centre on
           days 0, 1, 2, 3, 7, 14, 21, 28, 35 and 42. If a child is not seen at the health centre
           he/she will be visited at home.

           6. Data Management The principle investigator will ensure that the study protocol is
           strictly adhered to and that data are correctly collected and recorded on the case
           record form. Data will be entered into an EpiData database during the study.

           7. Sample size The PCR corrected day 42 ACPR of AL was 97% in 2008 ( = before the
           national recommendation was changed in favour of A). It is likely that DP should be as
           efficacious as AL and it is therefore appropriate to conduct a non-inferiority trial13.
           Assuming 97% ACPR for both treatments, 5% significance level (alpha), 80% power (1-beta)
           and a non-inferiority limit (d) of 5% 144 children are required in each arm. Assuming a
           20% loss to follow up a total of 346 children should be included.

           Analysis of data The data will be analysed using survival estimates of per protocol
           treatment failure rates but also intention to treat treatment failure rates. Final
           analysis will include a description of included children, proportions of adverse events
           and any serious adverse events, the proportion of children withdrawn or lost to follow
           up, the cumulative PCR corrected and uncorrected success and failure rates on day 42 and
           the proportion of early, late clinical and late parasitological treatment failures.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Adequate clinical and parasitological response rate
time frame: 42 days
description: The data will be analysed using survival estimates of per protocol treatment failure rates but also intention to treat treatment failure rates.
measure: the safety of AL and DP
time frame: 42 days
description: Self-reported signs and symptoms, clinical evaluations during treatment, day 7 and then weekly until day 42. leucocytes day 0, 3, 7, 14 and 21.
measure: To determine the capacity of each drug combination to protect against re-infection and to differentiate recrudescence from re-infections using PCR based methods
time frame: 42 days
measure: Genetic polymorphisms in P. falciparum causing reparasitaemia (by PCR) and in 50 children perform a characterisation of P. falciparum geno- and phenotypes.
time frame: 42 days
description: For all children with re-parasitaemia genetic polymorfisms will be established by PCR, and in additional 50 children further characterisation using cultures will be done
measure: haemoglobin values
time frame: days 0, 3 and 42
arm group label: Artemether-lumefantrine
arm group type: Active Comparator
description: 6-dose regime will be used:
arm group label: Dihydroartemisinin-piperaquine
arm group type: Active Comparator
description: A 3 dose regime will be used
intervention type: Drug
intervention name: Artemether-lumefantrine
arm group label: Artemether-lumefantrine
other name: Coartem (R)
intervention type: Drug
intervention name: Dihydroartemisinin-piperaquine
arm group label: Dihydroartemisinin-piperaquine
other name: Eurartesim
criteria: 
gender: All
minimum age: 6 Months
maximum age: 12 Years
healthy volunteers: No
facility: 
country: Guinea-Bissau
responsible party type: Sponsor
mesh term: Malaria
mesh term: Lumefantrine
mesh term: Artemether
mesh term: Piperaquine
mesh term: Artemether, Lumefantrine Drug Combination
mesh term: Artenimol